[韦德拉洛克通过调节铁亡来缓解过氧引起的急性肺损伤]
Junya Liu1, Song Qin1, Banghai Feng2
1Department of Critical Care Unit, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China.
Zhonghua wei zhong bing ji jiu yi xue
|November 21, 2023
概括
在小鼠中,Wedelolactone治疗通过调节关键细胞死亡途径ferroptosis,显著减少过氧诱导的急性肺损伤 (HALI). 这项研究为使用wedelolactone治疗HALI提供了理论基础.
科学领域:
- 生物医学研究的研究.
- 细胞和分子生物学是细胞和分子生物学.
- 肺部医学 肺部医学
背景情况:
- 过氧引起的急性肺损伤 (HALI) 是一种严重的疾病,治疗选择有限.
- 铁亡,一种受调节的细胞死亡形式,在HALI的发病过程中起着至关重要的作用.
- 确定HALI的新型治疗点至关重要.
研究的目的:
- 调查韦德拉洛克对HALI的保护作用.
- 为了确定Wedelolactone是否在HALI的背景下调节铁亡.
- 为Wedelolactone作为HALI的潜在治疗剂提供理论基础.
主要方法:
- 通过使用hyperoxia建立了HALI的小鼠模型.
- 韦德洛拉克被用腹膜内注射给先前治疗过的小鼠.
- 评估了肺部组织病理学,湿/干质量比,炎症性细胞因子水平 (TNF-α,IL-6,IL-1β),氧化应激标志物 (SOD,MDA,GSH) 和与铁死相关的蛋白GPX4表达.
主要成果:
- 哈利模型小鼠表现出显著的肺组织损伤,炎症标志物增加,氧化应激,和减少GPX4表达.
- 在Wedelolactone治疗前,肺损伤减轻,炎症和氧化应激减少,GPX4表达增加.
- 这些发现表明,wedelolactone通过抵消ferroptosis来减轻HALI.
结论:
- 韦德拉洛克显示出显著的保护作用,防止过氧引起的急性肺损伤.
- 该机制涉及铁灭的调节,突出其治疗潜力.
- 这项研究支持wedelolactone作为HALI药物开发的有希望的候选人.
相关概念视频
Necrosis
4.5K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.5K
Acute Respiratory Failure-II
243
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
243


